Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Zacks Research Issues Pessimistic Outlook for VRTX Earnings
Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...
Top Biotech Stocks To Research – March 4th
AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...
Benzinga.com16d
Analyst Expectations For Vertex Pharmaceuticals's Future
Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...
pharmaphorum19d
Vertex's latest cystic fibrosis combination approved in US
Symdeko is approved in patients aged 12 or over who have two copies of the F508del mutation in the CFTR gene, who have at least one mutation that is responsive to the drug. Approval was based on ...
StockNews12d
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Investing11d
Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc Aktie und aktueller Aktienkurs: Bleiben Sie über den aktuellen Aktienkurs von Vertex Pharmaceuticals Inc (VRTX) stets informiert - direkt auf dieser Seite. Behalten Sie ...